Kornimate/medical-research-clean huggingface dataset:
bilateral repetitive transcranial magnetic stimulation for auditory hallucinations results

Conditions: Schizophrenia

Summary: the primary purpose of this study was to conduct fmri neuroimaging studies prior to and subsequent to the rtms intervention. the intent was to ascertain changes in regional brain activation and connectivity that most robustly predict level of improvement in auditory hallucinations elicited by bilateral rtms as assessed by the primary outcome variables.

this study is an extension of previous clinical trials (nct00308997 and nct00567281) that were initiated in 2006. this study record provides the results for the amended study nct00567281 (originally called a 'third arm') that was discontinued following the passing of dr. ralph hoffman. the primary purpose of the study was to conduct fmri neuroimaging studies prior to and subsequent to the rtms intervention. the intent was to ascertain changes in regional brain activation and connectivity that most robustly predict level of improvement in auditory hallucinations elicited by bilateral rtms as assessed by our primary outcome variables. it was hoped that this combined fmri/rtms study would provide critical new insights into the neurobiological basis of auditory hallucinations. the results presented are what was summarized following dr. hoffman's passing and were compiled by dr. philip corlett.

Eligibility criteria:
inclusion criteria: * previously enrolled in our "parent" rtms trial with passage of at least six months since last received active rtms exclusion criteria: * active substance abuse or alcohol abuse * pregnancy * dose or type of psychiatric medication changed within the 4 weeks prior to study entry * recent head trauma, seizures, or significant unstable medical condition

Keywords: schizoaffective disorder auditory hallucinations voices repetitive transcranial magnetic stimulation rtms wernicke's area middle temporal cortex persistent auditory hallucinations previously participated in "parent" rtms protocol
effect of deep breathing exercises on post operative sleep duration

Conditions: Coronary Artery Bypass Graft

Summary: this study will provide the evidence that during the postoperative period deep breathing exercise combined with physical training can positively influence the sleep duration and quality. this study will provide the evidence that during the postoperative period deep breathing exercise combined with physical training can positively influence the sleep duration and quality.

subjects will be randomly placed into control group and interventional group. the control program will consist of deep breathing exercises (from morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive exercises. two daily sessions with an average duration of 25 min will be performed. in addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform additional deep breathing exercises (from morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days). deep breathing exercises will start 48 hours after extubation and full education along with the routine care (i.e.: from the fourth to sixth postoperative day).

Eligibility criteria:
inclusion criteria: * ability to read and write * stabilization of vital signs \[blood pressure, pulse, respiration) * patient undergoing off pump coronary artery bypass graft (cabg) procedure exclusion criteria: * history of severe mental diseases resulting in hospitalization and drug treatment within the previous 6 months * use any kind of other complementary methods such as massage therapy, aromatherapy, etc. to treat sleep disorders for the previous two weeks * history of sleep or respiration disorders and used cns medications in the night.

Keywords: breathing exercises coronary artery bypass sleep
intracameral mydriasis versus topical mydriasis in cataract surgery

Conditions: Cataract; Phacoemulsification; Mydriasis; Pseudoexfoliation Syndrome

Summary: the purpose is to determine if an intracameral solution of 0.2% tropicamide and 2% phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1% tropicamide and 5% phenylephrine. we will be looking at two separate groups of patients, those with and those without pseudoexfoliation syndrome. we will be looking at how each method affects the size of the pupil at the beginning and at the end of cataract surgery. in addittion, we will look at what effect the two different methods have on blood pressure and heart rate in the pre-operative, peri-operative and post-operative periods.


Eligibility criteria:
inclusion criteria: * ability to give consent * greater than 18 years of age * planned clear cornea cataract extraction and placement of foldable posterior chamber intraocular lens * no secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant, vitreo-retinal procedure etc.) * systemic condition capable of undergoing topical anesthesia * no previous intraocular surgery * pseudoexfoliation syndrome (pxf) for group 1 * no pseudoexfoliation syndrome for group 2 exclusion criteria: * not fulfilling inclusion criteria * any iris pathology including but not limited to posterior synechia, iridocorneal endothelial syndrome, corectopia, traumatic mydriasis, horner's syndrome, adie's pupil, cyclodialysis, iridodialysis * previous or concurrent use of flomax® or similar alpha-antagonist medication * corneal pathology affecting pupil magnification or measurement (keratoconus, peripheral thinning, sclerocornea, scarring) * uncontrolled hypertension (greater than 170/90 on pre-operative assessment on day of surgery as measured by automated datex monitor)

Keywords: cataract surgery phacoemulsification pupil dilation mydriasis intracameral topical pseudoexfoliation syndrome
study of satisfaction of patients and care providers for an alternate follow-up with in-hospital consults and tele-consult for patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the pandemic forced us to develop home follow-up for patients with chronical diseases . in the same time, the new era of treatment for cystic fibrosis considerably improves the health of patients with this pathology. this study aims to assess the satisfaction of patients and care providers for an alternated follow-up between tele-consults and in-hospital consults during one year for patients with cystic fibrosis treated by kaftrio® since at least one year and stable.


Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis * patients treated with kaftrio® since one year * autonomous patients * patients without cognitive disorders * patients voluntary for this follow up * patients with two tele-communication tools * patients with fev1\>50% * patients with less of 2 antibiotics cure per year exclusion criteria: * all transplanted patients * pregnant patients * particular follow up needed in-hospital consult * persons deprived of their liberty by a judicial or administrative decision * persons subject to psychiatric care * persons admitted to a health or social establishment for purposes other than research * persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Keywords: tele-medicine cystic fibrosis alternate follow-up
positron emission tomography (pet) during radio-chemotherapy to treat otorhinolaryngological cancer

Conditions: Malignant Neoplasm of Head and Neck; Locally Advanced Malignant Neoplasm

Summary: open multicentric study assessing predictive value of 18-fdg pet (suv max) at 20 gy during radio-chemotherapy, on the loco-regional control after 2 years


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and ≤ 75 years * invasive epidermoid carcinoma of head and neck (excluding nasopharyngeal), confirmed by histology * locally advanced disease (non-metastatic stages ajcc iii-iv). ajcc = american joint committee on cancer * performance status ecog ≤ 2. ecog = eastern cooperative oncology group * no history of irradiation of the head and neck * start of radiotherapy within 8 weeks after the pretreatment pet scan * no surgery other than biopsy * pregnancy test: negative for women of childbearing potential * reliable contraception for a childbearing couple, men and woman must have a reliable contraception during treatment * signed informed consent form * patient with national health insurance exclusion criteria: * prior radiotherapy or chemotherapy * history of other cancer except: cutaneous non-melanoma tumor and cervix in situ carcinoma * unstable conditions (cardiovascular, renal, pulmonary) or systemic (lupus erythematosus, scleroderma) * pregnant patient or patient with breastfeeding * patient unable to give his consent * patient under administrative supervision * patient who participates to another clinical trial on experimental drug * regular follow-up impossible for various reasons (familial, economical, social, ...) * diabetes * accelerated radiotherapy protocol
this study is to compare the efficacy of zd6474 and zd1839 in subjects with nsclc.

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to compare the efficacy of zd6474 and zd1839 in patients with nsclc after failure of prior platinum-based chemotherapy.


Eligibility criteria:
inclusion criteria: * failure of either first-line and/or second-line chemotherapy either of which was platinum-based (the prior regimen must have failed the subject because of toxicity or progression of tumor * prior histologic or cytologic confirmation of locally advanced or metastatic (iiib/iv) nsclc exclusion criteria: * subjects who have received second-line or subsequent chemotherapy * any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)

Keywords: nsclc locally advanced or metastatic second-line
acute management of humeral shaft fractures: sling vs. splint

Conditions: Fracture of Shaft of Humerus

Summary: when people break their arm and arrive at oregon health and science university's emergency department (ohsu ed), they are treated with a short-term means of immobilizing their broken arm. the two most common ways of stabilizing the broken parts of the arm are 1) with a plaster-based coaptation splint, or 2) with a soft cloth sling and swathe. these hold the arm steady until the patient can schedule an appointment with the ohsu orthopaedic trauma clinic where they will receive definitive evaluation and stabilization/fixation. in much of the orthopaedic literature coaptation splints are the default immobilization method. the investigators hypothesize however, that sling and swathe immobilization may be equally effective for short term stabilization, while being faster to apply, and more comfortable for the patient. this randomized, unblinded prospective study will follow the satisfaction, quality of life and limited functional outcomes of all enrolled participants during the first week following their injury.


Eligibility criteria:
inclusion criteria: * age 18-80 * acute midshaft humeral fracture within 48 hours exclusion criteria: * ed presentation more than 48 hours after injury * head injury * open fracture * pathological fracture * known pregnancy * inmate or prisoner * non-english speaking * sexual assault (sa) victim * patient and legally authorized representative unable to provide consent

Keywords: humerus fracture sling splint coaptation
effect of intermittent oro-esophageal tube feeding on dysphagic patients with parkinson disease

Conditions: Parkinson Disease

Summary: the goal of this or clinical trial is to explore intermittent oro-esophageal tube feeding vs. nasogastric tube feeding on nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease, better than nasogastric tube feeding. participants will be divided into the control group and observation group evenly. all the patients were provided with routine therapy and given nutritional support by intermittent oro-esophageal tube feeding and nasogastric tube feeding respectively. the nutritional status, swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

nasogastric tube feeding has been widely used in patients with parkinson's disease but has a significant risk of complications. intermittent oro-esophageal tube feeding is an established enteral nutrition approach that can be used with comprehensive rehabilitation therapy. the goal of this or clinical trial is to explore intermittent oro-esophageal tube feeding vs. nasogastric tube feeding on nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease, better than nasogastric tube feeding. participants will be divided into the control group and observation group evenly. all the patients were provided with routine therapy and given nutritional support by intermittent oro-esophageal tube feeding and nasogastric tube feeding respectively. the nutritional status, swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease developed by the neurology branch of the chinese medical association in 2006. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * water swallow test\> level 3. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases. * complicated with severe liver and kidney failure, tumors, or hematological disorders.
energy intake, exercise and energy replacement

Conditions: Pediatric Obesity

Summary: the aim of the present study is to compare the effect of an exercise alone versus. an exercise followed by the ingestion of an energy replacement snack on the following energy intake, food reward and appetite feelings in adolescents with obesity.

the present study will compare the nutritional response to the realisation of an acute exercise with and without an energy replacement snack on the following energy intake in adolescents with obesity. 18 adolescents with obesity will be asked to randomly complete three experimental sessions: i) one control session (rest); ii) one session with an acute exercise realized during the morning; iii) one session with the same exercise followed by a snack covering the exercise-induced energy expenditure. their ad libitum energy intake will be assessed at the following meal as well as at dinner time. appetite feelings will be assessed at regular intervals and their food reward in response to the lunch will also be assessed.

Eligibility criteria:
inclusion criteria: * bmi percentile \> 97th percentile according to the french curves. * ages 12-16 years old * signed consent form * being registered in the national social security system * no contraindication to physical activity exclusion criteria: * previous surgical interventions that is considered as non-compatible with the study. * diabetes * weight loss during the last 6 months * cardiovascular disease or risks

Keywords: appetite control obesity adolescents exercise energy replacement
a study of donanemab (ly3002813) compared with aducanumab in participants with early symptomatic alzheimer's disease (trailblazer-alz 4)

Conditions: Mild Cognitive Impairment (MCI); Alzheimer Disease

Summary: the main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic alzheimer's disease (ad).


Eligibility criteria:
inclusion criteria: * gradual and progressive change in memory function reported by the participant or informant for ≥6 months. * meet florbetapir f18 pet scan criteria. * a clinical dementia rating (cdr)-global score of 0.5 or 1. * must consent to apolipoprotein e (apoe) genotyping * must have a mini mental state examination (mmse) score between 20 and 30 * have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available by telephone at designated times. * have adequate literacy, vision, and hearing for neuropsychological testing in the opinion of the investigator at the time of screening. * women not of childbearing potential may participate exclusion criteria: * significant neurological disease affecting the central nervous system (other than ad), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures). * current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately ≤24 months. * history of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin a dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis). * history of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at ≤325 milligram (mg). * have had prior or current treatment with donanemab or aducanumab * have known allergies to donanemab or aducanumab, related compounds, or any components of the formulation * prior or current participation in any immunotherapy study targeting amyloid beta

Keywords: alzheimer's disease with mci or mild dementia
transcranial magnetic stimulation in episodic migraine (magnet-em)

Conditions: Migraine

Summary: this study will assess the safety and efficacy of repetitive transcranial magnetic stimulation (rtms) as new preventive treatment of migraine.

migraine patients according to international headache society criteria will be allocated randomly into two treatment arms. one group will receive active rtms and another group will receive sham rtms for treatment phase (5 sessions). assessment will be made at baseline, month 1, month 2 and month 3 post-treatment.

Eligibility criteria:
inclusion criteria: 1. males or females aged 18 to 60 years of age. 2. subjects fulfilling criteria for episodic migraine as per the third edition of the international headache society (ichd-3) for at least 1 year. 3. frequency of migraine attacks 2-8 times per month with less than 15 headache days per month for at least 3 months prior to screening. 4. demonstrated compliance with the headache diary during the run-in period by entry of headache data on a minimum of 24/30 days (80% compliance). 5. a signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments. exclusion criteria: 1. patients with previous history of rtms treatment. 2. onset of headache at more than 50-year-old. 3. headache with red flags symptoms that may suggest organic secondary headaches. 4. pregnant or lactating women. 5. patients with contraindications to tms such as metallic implant and pacemaker based on the screening 13-item questionnaire for rtms candidate. 6. patients with medical conditions such severe hypertension, infections, malignancy, cardiovascular and cerebrovascular disease, epilepsy degenerative central nervous system diseases, renal failure, hepatic failure, bleeding diathesis and serious mental illness.

Keywords: repetitive transcranial magnetic stimulation transcranial doppler neuromodulation randomized controlled trials pain migraine prophylaxis dorsolateral prefrontal cortex protocol
prospective post market clinical follow-up of the primary knee endoprosthesis bpk-s integration

Conditions: Osteoarthritis, Knee; Joint Instability

Summary: prospective, monocenter post market clinical follow-up of a primary knee replacement bearing the ce-mark. 200 subjects will be recruited and followed up for up to ten years or until revision of the primary knee endoprosthesis, whichever occurs first. documentation of clinical and radiological parameters within the clinical routine pre-operative and post-operative at 3 and 12 months and 2, 5 and 10 years to evaluate time to revision, pain situation, knee functionality, mobility and stability.


Eligibility criteria:
inclusion criteria: * congenital or acquired knee joint defects/deformation or * defects or malfunction of the knee joint or * arthrosis (degenerative, rheumatic) or * post-traumatic arthritis or * symptomatic knee instability or * reconstruction of flexibility or * patients with metal hypersensitivity (ceramic tibia/femur) exclusion criteria: * illnesses which can be treated without using a knee joint implant. * acute or chronic infections near the implantation * systemic diseases and metabolic disorders * serious osteoporosis * serious damage to the bone structures that impedes stable implantation of the implant components * diseases that impair bone growth, e.g. cancer, renal dialysis, osteopenia, etc. * bone tumors in the area of the implant anchoring * obesity or overweight of the patient * overload of the knee implant to be expected * abuse of medication, drug abuse, alcoholism or mental disease * lack of patient cooperation * sensitivity to foreign matter in the implant materials * patients under the age of 18 * patients participating in another trial

Keywords: primary tkr
transversus thoracic plane block for perioperative analgesia in cardiac surgery

Conditions: Transversus Thoracic Plane Block; Cardiac Surgery; Post Operative Pain

Summary: the goal of this clinical trial is to learn if perioperative transversus thoracic plane block (ttpb) decrease perioperative pain after cardiac surgery. the main questions it aims to answer are: 1. does transversus thoracic plane block decrease perioperative pain after cardiac surgery more than the standard analgesic treatment? 2. are the results different if the investigators perform transversus thoracic plane block before surgery or at the end of surgery?


Eligibility criteria:
inclusion criteria: - all patients scheduled for cardiac surgery via sternotomy under cardiopulmonary bypass exclusion criteria: * previous cardiac surgery * urgent surgery * pregnant women * allergy to local anesthetics * opioid dependence * low ejection fraction \< 30% * presence or onset of cognitive or neurological disorders preventing pain assessment * infection at injection sites * coagulopathy * patients on dual antiplatelet therapy * renal insufficiency with glomerular filtration rate (gfr) \< 30 ml/min * history of thoracic radiotherapy * history of mastectomy